BOSTON DR LIM

BIOTECH (104) Novartis: Pluvicto (177Lu-PSMA-617) – the First Precision Radiopharmaceuticals

March 2, 2024March 2, 2024

BIOTECH (103) Prime Medicine: Prime Editing

March 2, 2024March 2, 2024

BIOTECH (102) Elicio Therapeutics: Albumin-Hitchhiking Vaccine Amphiphile (AMP) Platform

March 1, 2024March 1, 2024

BIOTECH (101) Krystal Biotech: Redosable HSV-1 vector gene therapy – Vijuvek (beremagene geperpavec)

March 1, 2024March 1, 2024

BIOTECH (100) PureHealth Tech: Glyph – Lymphatic Delivery Platform

March 1, 2024March 1, 2024

BIOTECH (99) BlueRock Therapeutics: Bemdaneprocel (BRT-DA01, MSK-DA01) – Autologous Stem Cell Therapy for Parkinson’s Disease

March 1, 2024March 1, 2024

BIOTECH (98) Basking Biosciences: Bruce Sullenger’s Reversable RNA Aptamer Platform

March 1, 2024March 1, 2024

BIOTECH (97) Tome Biosciences: Programmable Genomic Integration (PGI) Platform

February 29, 2024February 29, 2024

BIOTECH (96) – Janux Therapeutics: Tumor Activated Masked T-Cell Engager (TRACTr) Platform

February 29, 2024

BIOTECH (95) – Ikena Oncology – Rebranding and Restructuring from Discovery to Clinical Focus

February 23, 2024February 23, 2024